Mariko Takeda-Morishita

Prof. Mariko Takeda-Morishita

Kobe Gakuin University
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
ENEbbe Juel Bech Nielsen
Ebbe Juel Bech Nielsen
SYShinya Yoshida
Shinya Yoshida
NKNoriyasu Kamei
Noriyasu Kamei
RIRuisha Iwamae
Ruisha Iwamae
EKEl-Sayed Khafagy
El-Sayed Khafagy
MTMariko Takeda-Morishita
Mariko Takeda-Morishita

1 January 2015 in Journal of Controlled Release
Verified
Journal Article
Closed access
NKNoriyasu Kamei
Noriyasu Kamei
MTMariko Takeda-Morishita
Mariko Takeda-Morishita

1 November 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
NKNoriyasu Kamei
Noriyasu Kamei
YOYoshinori Onuki
Yoshinori Onuki
KTKozo Takayama
Kozo Takayama
MTMariko Takeda-Morishita
Mariko Takeda-Morishita

5 December 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NKNoriyasu Kamei
Noriyasu Kamei
NONobuyuki Okada
Nobuyuki Okada
TITakamasa Ikeda
Takamasa Ikeda
HCHayoung Choi
Hayoung Choi
YFYui Fujiwara
Yui Fujiwara
MTMariko Takeda-Morishita
Mariko Takeda-Morishita
In a recent study, we demonstrated the potential of a cell-penetrating peptide (CPP) penetratin to deliver the peptide drug insulin to the brain via nasal administration, and its pharmacological effect on the mild cognitive dysfunction in senescence-accelerated mouse (SAMP8). However, the therapeutic potential of intranasal insulin administration was attenuated when applied to the aged SAMP8 with severe cognitive dysfunction. The present study, therefore, aimed to overcome the difficulty in treating severe cognitive dysfunction using insulin by investigating potential alternatives, glucagon-like peptide-1 (GLP-1) receptor agonists such as exendin-4. Examination using normal ddY mice demonstrated that the distribution of exendin-4 throughout the brain was dramatically increased by intranasal coadministration with the L-form of penetratin. The activation of hippocampal insulin signaling after the simultaneous nose-to-brain delivery of exendin-4 and an adequate level of insulin were confirmed by analyzing the phosphorylation of Akt. Furthermore, spatial learning ability, evaluated in the Morris water maze test after daily administration of exendin-4 with L-penetratin and supplemental insulin for 4 weeks, suggested therapeutic efficacy against severe cognitive dysfunction. The present study suggests that nose-to-brain delivery of exendin-4 with supplemental insulin, mediated by CPP coadministration, shows promise for the treatment of progressive cognitive dysfunction in SAMP8.

27 January 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
NKNoriyasu Kamei
Noriyasu Kamei
MTMisa Tanaka
Misa Tanaka
HCHayoung Choi
Hayoung Choi
NONobuyuki Okada
Nobuyuki Okada
TITakamasa Ikeda
Takamasa Ikeda
MTMariko Takeda-Morishita
Mariko Takeda-Morishita

1 February 2013 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
PDF file
NKNoriyasu Kamei
Noriyasu Kamei
SKShingo Kikuchi
Shingo Kikuchi
MTMariko Takeda-Morishita
Mariko Takeda-Morishita
YTYoshiaki Terasawa
Yoshiaki Terasawa
AYAkihito Yasuda
Akihito Yasuda
KTKozo Takayama
Kozo Takayama